PTPA and cancer: Because the FAM122A E92K mutation was identified in cancer tissues (cBioPortal), we also generated E91K and E92K variants and showed they also bound PP2A:B55 less strongly and were less potent inhibitors of PP2A:B55 (Extended Data Tables 1 and 2 and Extended Data Fig. 2a,b).